Companies in #Ophthalmology

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is an American generics and specialty pharmaceutical company founded in 2002 by brothers Chirag and Chintu Patel, headquartered in Bridgewater, New Jersey with major manufacturing operations in India and a growing US footprint. Amneal develops, manufactures, and distributes generic and specialty pharmaceuticals across multiple dosage forms including oral solids, injectables, topicals, and ophthalmics. The company is one of the largest US-based generic drug manufacturers and has been actively reshuffling its US footprint to focus on higher-value categories including sterile injectables, biosimilars, and complex generics. Amneal was selected in June 2026 for the FDA PreCheck Pilot Program for its new Long Island, NY facility that will manufacture small molecule sterile liquid products for pain management, respiratory and ophthalmic diseases.

Bausch + Lomb is a public eye-health company focused on vision care, surgical ophthalmology, and ophthalmic pharmaceuticals.

Bayer (ETR: BAYN) is a diversified life sciences company headquartered in Leverkusen, Germany.

City Therapeutics is a clinical-stage biotechnology company pioneering next-generation RNA interference (RNAi) medicines, founded by John Maraganore (former CEO of Alnylam Pharmaceuticals) and a team of RNAi pioneers. The company's lead platform is based on cleavage-inducing tiny guide RNAs (cityRNAs) designed to improve potency and durability over first-generation siRNA therapeutics, with three programs in the pipeline targeting cardiometabolic and rare diseases.

Claris Bio is a ophthalmology company. See today's news for the latest developments.

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

Chinese biotech developing innovative biologics including monoclonal antibodies and bispecifics for oncology, ophthalmology, and autoimmune diseases.

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for rare and severe diseases of the eye, leveraging the company's proprietary mesenchymal stem cell secretome-based technology platform. Following the May 8, 2026 1-for-50 reverse stock split (reducing outstanding shares to approximately 18.6M to address Nasdaq's $1.00 minimum bid price requirement), the company continues to operate under the KALA ticker. The January 2026 424B5 prospectus supplement established a $15M at-the-market common-stock program through H.C. Wainwright. KALA's pipeline targets ophthalmic indications with high unmet need including persistent corneal epithelial defect (PCED) and rare anterior segment inflammatory conditions.

London-based gene therapy company developing treatments for Parkinson's disease, radiation-induced xerostomia, and inherited retinal diseases, using proprietary Riboswitch gene regulation platform.

Ollin Biosciences is a clinical-stage ophthalmology company developing a next-generation anti-VEGF challenger to Regeneron's Eylea and Roche's Vabysmo for retinal disease. The company raised a $330M Series B in 2026 to fund pivotal Phase 3 trials of its lead asset.

Osanni Bio is a San Francisco-based biotechnology company building a pipeline of therapeutics for ophthalmology and cardiology indications. The company raised $190M in 2026 to advance its portfolio of small-molecule and biologic candidates addressing high-prevalence vision and cardiovascular diseases.

Outlook Therapeutics is a ophthalmology company. See today's news for the latest developments.

Ophthalmic medical device company (NASDAQ: SGHT) developing and commercializing surgical and nonsurgical technologies for prevalent eye diseases. Its Surgical Glaucoma segment markets the OMNI family of implant-free minimally invasive glaucoma surgery systems (OMNI Ergo, OMNI EDGE) and the SION bladeless excisional device; its Dry Eye segment markets the TearCare interventional dry eye system for evaporative dry eye disease. Q2 2026 revenue grew roughly 20% year over year, prompting the company to raise full-year 2026 revenue guidance and lower adjusted operating expense guidance, and the stock gained about 28% in a single August 2026 session.

Late clinical-stage biopharma developing therapeutic solutions for chronic diseases in eye care and beyond; lead product XDEMVY (lotilaner ophthalmic solution 0.25%) is the first and only FDA-approved treatment for Demodex blepharitis. In August 2026 it agreed to acquire Alkeus Pharmaceuticals and its Phase 3 Stargardt disease drug for $450 million.